These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26717965)

  • 1. HIF-1α/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer.
    Sun Y; Guan Z; Liang L; Cheng Y; Zhou J; Li J; Xu Y
    Oncol Rep; 2016 Mar; 35(3):1549-56. PubMed ID: 26717965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression.
    Sun Y; Guan Z; Liang L; Cheng Y; Zhou J; Li J; Xu Y
    Int J Oncol; 2016 Jan; 48(1):225-34. PubMed ID: 26647959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.
    Li Y; Zhao X; Tang H; Zhong Z; Zhang L; Xu R; Li S; Wang Y
    Urol Int; 2012; 88(1):95-101. PubMed ID: 22041818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF-κB signal-dependent and signal-independent manner.
    Sun Y; Guan Z; Zhao W; Jiang Y; Li Q; Cheng Y; Xu Y
    Int J Oncol; 2017 Oct; 51(4):1219-1226. PubMed ID: 28791405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
    Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
    J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-mediated attenuation of EGLN2 inhibition of the NF-κB signaling pathway leads to the formation of a loop between HIF-1α and MUC1-C promoting chemoresistance in bladder cancer.
    Qing L; Li Q; Yang Y; Xu W; Wang Y; Li R; You C; Dong Z
    Mol Carcinog; 2024 Jul; 63(7):1303-1318. PubMed ID: 38634741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR‑214 reduces cisplatin resistance by targeting netrin‑1 in bladder cancer cells.
    Liu J; Bi J; Li Z; Li Z; Liu X; Kong C
    Int J Mol Med; 2018 Mar; 41(3):1765-1773. PubMed ID: 29328435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia regulates the expression and localization of CCAAT/enhancer binding protein α by hypoxia inducible factor-1α in bladder transitional carcinoma cells.
    Xue M; Li X; Chen W
    Mol Med Rep; 2015 Aug; 12(2):2121-7. PubMed ID: 25824695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
    Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
    Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.
    Ao Q; Su W; Guo S; Cai L; Huang L
    Sci Rep; 2015 Nov; 5():16396. PubMed ID: 26548925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CIRBP is a novel oncogene in human bladder cancer inducing expression of HIF-1α.
    Lu M; Ge Q; Wang G; Luo Y; Wang X; Jiang W; Liu X; Wu CL; Xiao Y; Wang X
    Cell Death Dis; 2018 Oct; 9(10):1046. PubMed ID: 30315244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KLF1 Activates RAC3 to Mediate Fatty Acid Synthesis and Enhance Cisplatin Resistance in Bladder Cancer Cells.
    Song L; Xu Q; Chen R; Sun W; Zhan J
    Am J Mens Health; 2024; 18(5):15579883241273305. PubMed ID: 39376007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation.
    Li X; Wang H; Wang J; Chen Y; Yin X; Shi G; Li H; Hu Z; Liang X
    BMC Cancer; 2016 Aug; 16():578. PubMed ID: 27485374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
    Li Y; Zu X; Hu X; Wang L; He W
    Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
    Duyndam MC; van Berkel MP; Dorsman JC; Rockx DA; Pinedo HM; Boven E
    Biochem Pharmacol; 2007 Jul; 74(2):191-201. PubMed ID: 17498666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
    Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
    Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-induced increases in A549/CDDP cell drug resistance are reversed by RNA interference of HIF-1α expression.
    Min L; Chen Q; He S; Liu S; Ma Y
    Mol Med Rep; 2012 Jan; 5(1):228-32. PubMed ID: 21964646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension.
    Peixoto A; Fernandes E; Gaiteiro C; Lima L; Azevedo R; Soares J; Cotton S; Parreira B; Neves M; Amaro T; Tavares A; Teixeira F; Palmeira C; Rangel M; Silva AM; Reis CA; Santos LL; Oliveira MJ; Ferreira JA
    Oncotarget; 2016 Sep; 7(39):63138-63157. PubMed ID: 27542232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.